GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ascendis Pharma A/S (NAS:ASND) » Definitions » Beneish M-Score

Ascendis Pharma A/S (Ascendis Pharma A/S) Beneish M-Score

: 0.41 (As of Today)
View and export this data going back to 2015. Start your Free Trial

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Warning Sign:

Beneish M-Score 0.41 higher than -1.78, which implies that the company might have manipulated its financial results.

The historical rank and industry rank for Ascendis Pharma A/S's Beneish M-Score or its related term are showing as below:

ASND' s Beneish M-Score Range Over the Past 10 Years
Min: -3.09   Med: -0.89   Max: 3.39
Current: 0.41

During the past 13 years, the highest Beneish M-Score of Ascendis Pharma A/S was 3.39. The lowest was -3.09. And the median was -0.89.


Ascendis Pharma A/S Beneish M-Score Historical Data

The historical data trend for Ascendis Pharma A/S's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ascendis Pharma A/S Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Beneish M-Score
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.25 -0.47 -0.89 -0.27 0.41

Ascendis Pharma A/S Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Beneish M-Score Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.27 -0.28 0.49 -0.29 0.41

Competitive Comparison

For the Biotechnology subindustry, Ascendis Pharma A/S's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ascendis Pharma A/S Beneish M-Score Distribution

For the Biotechnology industry and Healthcare sector, Ascendis Pharma A/S's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Ascendis Pharma A/S's Beneish M-Score falls into.



Ascendis Pharma A/S Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Ascendis Pharma A/S for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.4146+0.528 * 0.9096+0.404 * 0.4343+0.892 * 5.4046+0.115 * 0.8394
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.2273+4.679 * -0.027821-0.327 * 1.6468
=0.41

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Dec22) TTM:
Total Receivables was $60.8 Mil.
Revenue was 150.166 + 51.264 + 51.347 + 35.963 = $288.7 Mil.
Gross Profit was 128.948 + 43.379 + 37.339 + 31.015 = $240.7 Mil.
Total Current Assets was $766.3 Mil.
Total Assets was $900.3 Mil.
Property, Plant and Equipment(Net PPE) was $120.6 Mil.
Depreciation, Depletion and Amortization(DDA) was $20.4 Mil.
Selling, General, & Admin. Expense(SGA) was $285.0 Mil.
Total Current Liabilities was $215.2 Mil.
Long-Term Debt & Capital Lease Obligation was $674.9 Mil.
Net Income was -94.742 + -173.13 + -131.563 + -118.752 = $-518.2 Mil.
Non Operating Income was 26.255 + -7.251 + -8.073 + -1.314 = $9.6 Mil.
Cash Flow from Operations was -46.314 + -133.105 + -165.902 + -157.435 = $-502.8 Mil.
Total Receivables was $27.1 Mil.
Revenue was 24.254 + 15.139 + 6.512 + 7.52 = $53.4 Mil.
Gross Profit was 18.839 + 13.462 + 5.364 + 2.844 = $40.5 Mil.
Total Current Assets was $978.3 Mil.
Total Assets was $1,154.4 Mil.
Property, Plant and Equipment(Net PPE) was $136.8 Mil.
Depreciation, Depletion and Amortization(DDA) was $18.9 Mil.
Selling, General, & Admin. Expense(SGA) was $232.0 Mil.
Total Current Liabilities was $181.4 Mil.
Long-Term Debt & Capital Lease Obligation was $511.6 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(60.821 / 288.74) / (27.146 / 53.425)
=0.210643 / 0.508114
=0.4146

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(40.509 / 53.425) / (240.681 / 288.74)
=0.758241 / 0.833556
=0.9096

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (766.326 + 120.648) / 900.313) / (1 - (978.253 + 136.753) / 1154.383)
=0.014816 / 0.034111
=0.4343

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=288.74 / 53.425
=5.4046

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(18.886 / (18.886 + 136.753)) / (20.389 / (20.389 + 120.648))
=0.121345 / 0.144565
=0.8394

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(285.042 / 288.74) / (232.013 / 53.425)
=0.987193 / 4.34278
=0.2273

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((674.88 + 215.206) / 900.313) / ((511.606 + 181.431) / 1154.383)
=0.988641 / 0.600353
=1.6468

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-518.187 - 9.617 - -502.756) / 900.313
=-0.027821

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Ascendis Pharma A/S has a M-score of 0.41 signals that the company is likely to be a manipulator.


Ascendis Pharma A/S Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Ascendis Pharma A/S's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Ascendis Pharma A/S (Ascendis Pharma A/S) Business Description

Traded in Other Exchanges
Address
Tuborg Boulevard 12, Hellerup, DNK, DK-2900
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates in North America, China, and Europe and derives the majority of its revenue from North America.

Ascendis Pharma A/S (Ascendis Pharma A/S) Headlines

From GuruFocus

Ascendis Pharma to Host Oncology Program Update on May 31

By sperokesalga sperokesalga 05-25-2023